Spots Global Cancer Trial Database for interleukin 2
Every month we try and update this database with for interleukin 2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | NCT05704985 | Cancer Solid Tumor Colorectal Canc... Pancreas Cancer Non Small Cell ... Head and Neck C... Gynecologic Can... Skin Cancer Kidney Cancer | DK210 (EGFR) Radiation thera... Immune checkpoi... Chemotherapy | 18 Years - | DEKA Biosciences | |
| Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan | NCT02776644 | Renal Cell Carc... | - | Pfizer | ||
| Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors | NCT01662804 | Neuroblastoma | 3F8 Monoclonal ... | 13 Months - | Memorial Sloan Kettering Cancer Center | |
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | NCT04009681 | Metastasis | THOR-707 Checkpoint inhi... anti-EGFR antib... | 18 Years - | Synthorx, Inc, a Sanofi company | |
| Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma | NCT02278887 | Metastatic Mela... | Translational r... Cyclophosphamid... Fludarabine Interleukin-2 Ipilimumab infu... | 18 Years - 75 Years | The Netherlands Cancer Institute | |
| Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma | NCT02278887 | Metastatic Mela... | Translational r... Cyclophosphamid... Fludarabine Interleukin-2 Ipilimumab infu... | 18 Years - 75 Years | The Netherlands Cancer Institute | |
| Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia | NCT01347996 | Acute Myeloid L... | histamine dihyd... | 18 Years - | Cytovia, Inc. | |
| Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. | NCT01416831 | Metastatic Mela... | Radiation thera... High-dose IL-2 | 18 Years - | Providence Health & Services | |
| IL2 Imaging in Metastatic Melanoma | NCT02922283 | Melanoma | IL2-PET scan Tumor biopsy CT scan Biopsy of non-t... | 18 Years - | University Medical Center Groningen | |
| Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan | NCT02776644 | Renal Cell Carc... | - | Pfizer | ||
| NY-ESO-1 T Cells in OG Cancer | NCT01795976 | Oesophageal Can... | NY-ESO-1 T cell... cyclophosphamid... Fludarabine Interleukin 2 | 18 Years - | The Christie NHS Foundation Trust | |
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | NCT04009681 | Metastasis | THOR-707 Checkpoint inhi... anti-EGFR antib... | 18 Years - | Synthorx, Inc, a Sanofi company | |
| Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma | NCT00970996 | Melanoma | Temozolomide Abraxane Cisplatin Interleukin-2 Interferon alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors | NCT01662804 | Neuroblastoma | 3F8 Monoclonal ... | 13 Months - | Memorial Sloan Kettering Cancer Center | |
| Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML | NCT04887259 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... | LAVA-051 Interleukin 2 | 18 Years - | Lava Therapeutics | |
| Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia | NCT01347996 | Acute Myeloid L... | histamine dihyd... | 18 Years - | Cytovia, Inc. | |
| Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors | NCT00002994 | Unspecified Adu... | interleukin 2 rhuMAb | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors | NCT00002994 | Unspecified Adu... | interleukin 2 rhuMAb | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors | NCT01662804 | Neuroblastoma | 3F8 Monoclonal ... | 13 Months - | Memorial Sloan Kettering Cancer Center | |
| Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma | NCT00970996 | Melanoma | Temozolomide Abraxane Cisplatin Interleukin-2 Interferon alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients | NCT00553618 | Metastatic Mela... | Proleukin and D... | 18 Years - | University of Louisville | |
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | NCT04009681 | Metastasis | THOR-707 Checkpoint inhi... anti-EGFR antib... | 18 Years - | Synthorx, Inc, a Sanofi company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
